In conclusion, these results should provide incentives for further investigation and optimization in establishing the mechanistic role of HIF-1α and NF-κB in the attenuation of EMT characteristics and drug resistance and their utility in the clinical setting for the treatment of pancreatic cancer for which there is no effective and curative therapy. The gene discussed is NFKB1; the disease is familial pancreatic carcinoma.